` INTS (Intensity Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

INTS
vs
S&P 500

Over the past 12 months, INTS has significantly outperformed S&P 500, delivering a return of +548% compared to S&P 500's +10% growth.

Stocks Performance
INTS vs S&P 500

Loading...
INTS
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
INTS vs S&P 500

Loading...
INTS
S&P 500
Difference
www.alphaspread.com

Performance By Year
INTS vs S&P 500

Loading...
INTS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Intensity Therapeutics Inc vs Peers

S&P 500
INTS
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Intensity Therapeutics Inc
Glance View

Market Cap
9.1m USD
Industry
Biotechnology

Intensity Therapeutics is a clinical-stage biotechnology company that develops cancer treatments designed to be injected directly into a tumor. Its approach uses the tumor itself to help trigger an immune response, with the goal of shrinking the injected tumor and helping the body attack cancer elsewhere. The company’s lead work is focused on solid tumors, where doctors and cancer centers would be the users if the therapies reach market. The company does not sell approved drugs yet, so it does not have a traditional commercial customer base. Today it funds its work through equity financing and, if it signs them, research or licensing partnerships with larger drug companies. If its treatments are approved in the future, it would likely make money from product sales, licensing fees, and possible royalties. What makes Intensity Therapeutics different is that it is trying to turn a tumor into part of the treatment process instead of relying only on medicines that circulate through the whole body. That could fit alongside surgery, radiation, and other cancer drugs, and it gives the company a shot at becoming a specialty oncology developer focused on local tumor treatment rather than a broad drug maker.

INTS Intrinsic Value
$16.5804
Undervaluation 83%
Intrinsic Value
Price $2.7878
Back to Top